Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Oct 15, 2024; 15(10): 2006-2009
Published online Oct 15, 2024. doi: 10.4239/wjd.v15.i10.2006
Utilising continuous glucose monitoring for glycemic control in diabetic kidney disease
Vamsidhar Veeranki, Narayan Prasad
Vamsidhar Veeranki, Narayan Prasad, Department of Nephrology and Renal Transplantation, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, Uttar Pradesh, India
Author contributions: Veeranki V and Prasad N contributed to this paper; Veeranki V designed the overall concept and outline of the manuscript; Prasad N contributed to the discussion and design of the manuscript; Veeranki V and Prasad N contributed to the writing, and editing the manuscript, illustrations, and review of literature; Both the authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Narayan Prasad, MD, Professor, Department of Nephrology and Renal Transplantation, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Rae Bareli Road, Lucknow 226014, Uttar Pradesh, India. narayan.nephro@gmail.com
Received: March 28, 2024
Revised: June 7, 2024
Accepted: July 9, 2024
Published online: October 15, 2024
Processing time: 181 Days and 15.4 Hours
Core Tip

Core Tip: Continuous glucose monitoring (CGM) emerges as a transformative tool, offering real-time insights into glycemic variability among diabetic patients with chronic kidney disease (CKD), particularly during dialysis and post-transplantation phases. Innovations include CGM's ability to accurately detect hyper- and hypoglycemic events, aiding in timely therapeutic adjustments to mitigate risks. Studies demonstrate CGM's superiority over traditional markers like glycated haemoglobin in capturing acute glycemic fluctuations, particularly in dialysis patients, mainly due to the shorter life span of red blood cells, besides maintaining accuracy across all CKD stages, including those on peritoneal dialysis. CGM has substantive potential in individualized glycaemic management of CKD.